Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

REDWOOD CITY, Cal., May 02, 2022 (Globe Newswire) — Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company that enables the promise of synthetic biology, today announced two poster presentations highlighting the company’s three gene therapy programs. Using directed evolution to potentially improve treatment options for hemophilia A and lysosomal storage diseases in American Society of Gene and Cell Therapy (ASGCT) 25th Annual meeting to be held in Washington, DC and virtually from May 16 to May 19, 2022.

The details of the poster presentations are as follows:

Topic: Towards an improvement in the treatment of hemophilia A with direct development of the factor VIII transgene
Session Name: Hematologic and Immunologic Diseases I
Session Date/Time: Monday, May 16, 2022, 5:30 pm ET
Presenter: Dr. Marcus Rohovi, Senior Scientist, Codexis, Inc.
the posters #: M-245

Topic: Overcoming therapeutic deficiencies in lysosomal storage disease treatment using directed evolution
Session Name: Metabolic, storage, endocrine, hepatic and gastrointestinal diseases.
Session Date/Time: Monday, May 16, 2022, 5:30 pm ET
Presenter: Dr. Rachel C. Botham, Senior Scientist, Codexis, Inc.
the posters #: M-131

Full abstracts are available through the ASGCT website. The posters will be made available through the ASGCT website and on the Codexis website from May 16, 2022.

About the Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeDeveloper Platform for discovery and development of novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food and industrial products; in manufacturing the next generation of life science instruments; and as gene therapy and oral enzyme therapy. The company’s unique performance promotes enzyme improvements such as: reduced energy use, waste generation and capital requirements; high yields; high fidelity diagnostics; more effective therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information visit

forward-looking statements

The statements contained in this press release are not statements of historical facts about Codexis, they are forward-looking statements reflecting management’s current beliefs and expectations in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that, in some cases, are beyond Codexis’ control and which could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) dated February 28, 2022, which states “Risk factor” heading. and other periodic reports of Codexis filed with the SEC. Codexis disclaims any intention or obligation to update these forward-looking statements, except as expressly required by law.


Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902
[email protected]

Stay Connected With Us On Social Media Platforms For Instant Updates Click Here To Connect With Us TeaveterAnd Facebook

we are on now wire. Click here to join our channel (@TechiUpdate) And stay updated with the latest technology headlines.

for all the latest Health News Click Here

Follow us on Google News for the latest news and updates,

read original article here

Denial of responsibility! is an automated aggregator around global media. All the material is available free of cost on the internet. We have arranged it on one platform only for educational purpose. In each material, a hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all content belongs to their authors. If you are the owner of the content and do not want us to publish your content on our website, please contact us E-mail – [email protected], Content will be removed within 24 hours.

Post Codexis to present data highlighting three gene therapy programs at ASGCT 25th Annual Meeting first appeared,

Source link

Leave a Comment